[Federal Register Volume 64, Number 67 (Thursday, April 8, 1999)]
[Notices]
[Page 17193]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 99-8668]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Exclusive License; A3 Adenosine 
Receptor Agonists and Antagonists

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 
CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), 
Department of Health and Human Services, is contemplating the grant of 
an exclusive license worldwide to practice the invention embodied in: 
U.S. Patent Applicant Serial No. 60/092,292 filed July 10, 1998 
entitled ``A3 Adenosine Receptor Antagonist'', PCT 
application US97/01252 filed January 29, 1997 designating the U.S. 
entitled ``Dihydropyridine, Pyridine, Benzophyranone and 
Triazoloquinazolone Derivatives Their Preparation And Their Use As 
Adenosine Receptor Antagonists'' and 08/091,109 filed July 13, 1993 and 
abandoned and refiled as 08/163,324 on December 6, 1993 also now 
abandoned and refiled as 08/274,628 now issued as U.S. Patent No. 
5,773,423 June 30, 1998 entitled ``A3 Adenosine Receptor 
Agonists'', to Gilead Sciences, having a place of business in Foster 
City, California. The United States of America is the assignee of the 
patent rights in this invention.

DATES: Only written comments and/or application for a license which are 
received by the NIH Office of Technology Transfer on or before July 7, 
1999 will be considered.

ADDRESSES: Requests for a copy of the patent applications, inquiries, 
comments and other materials relating to the contemplated license 
should be directed to: Charles Maynard, Technology Licensing 
Specialist, Office of Technology Transfer, National Institutes of 
Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804; 
Telephone: (301) 496-7056, ext. 243; Facsimile: (301) 402-0220; E-mail: 
[email protected].

SUPPLEMENTARY INFORMATION: In an effort to develop an efficacious 
treatment involving the collection of various technology involving 
Adenosine receptors, the inventors posit that Adenosine may play 
several key physiological roles. In addition to its role in 
intermediary metabolism, adenosine displays a number of receptor-
mediated physiological actions, including dilation of coronary vessels, 
inhibition of platelet aggregation, and inhabitation of lipolysis.
    The prospective exclusive license will be royalty-bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. 
The prospective exclusive license may be limited to the field of human 
therapeutics and may be granted unless, within 90 days from the date of 
this published Notice, NIH receives written evidence and argument that 
establishes that the grant of the license would not be consistent with 
the requirements of 35 U.S.C. 209 and 37 CFR 404.7.
    Property filed competing applications for a license filed in 
response to this notice will be treated as objections to the 
contemplated license. Comments and objections submitted to response to 
this notice will not be made available for public inspection, and, to 
the extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552.

    Dated: March 30, 1999.
Jack Spiegel,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer.
[FR Doc. 99-8668 Filed 4-7-99; 8:45 am]
BILLING CODE 4140-01-M